药品审批更新。
Pharmaceutical Approval Update.
作者信息
Kaufman Michele B
出版信息
P T. 2018 Jan;43(1):22-60.
Abstract
Latanoprostene bunod ophthalmic solution (Vyzulta) for the reduction of intraocular pressure; letermovir (Prevymis) for prophylaxis of cytomegalovirus infection and disease after stem cell transplant; benralizumab (Fasenra) for the add-on maintenance treatment of severe asthma of an eosinophilic phenotype.
摘要
用于降低眼压的拉坦前列素贝诺酯眼用溶液（Vyzulta）；用于预防干细胞移植后巨细胞病毒感染和疾病的来特莫韦（Prevymis）；用于嗜酸性粒细胞表型重度哮喘附加维持治疗的贝那利珠单抗（Fasenra）。
相似文献
1
Pharmaceutical Approval Update.药品审批更新。
P T. 2018 Jan;43(1):22-60.
2
Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.拉坦前列素苯扎洛尔滴眼液 0.024%：用于开角型青光眼和高眼压症的评价。
Drugs. 2018 May;78(7):773-780. doi: 10.1007/s40265-018-0914-6.
3
Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.0.024%比马前列素贝美素与0.5%噻吗洛尔降低24小时眼压的疗效比较。
Am J Ophthalmol. 2016 Sep;169:249-257. doi: 10.1016/j.ajo.2016.04.019. Epub 2016 Jul 22.
4
Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.用于降低青光眼和高眼压症眼压的0.024%拉坦前列素倍他米松眼用溶液
Expert Opin Pharmacother. 2017 Mar;18(4):433-444. doi: 10.1080/14656566.2017.1293654. Epub 2017 Feb 20.
7
Letermovir (Prevymis) for CMV prophylaxis.来特莫韦（普瑞明）用于巨细胞病毒预防。
Med Lett Drugs Ther. 2019 Dec 16;61(1587):199-201.
8
[Pharmacological and clinical effects of letermovir (Prevymis), a novel anti-human cytomegalovirus prophylactic drug].新型抗人巨细胞病毒预防药物来特莫韦（Prevymis）的药理及临床效果
Nihon Yakurigaku Zasshi. 2019;153(4):192-198. doi: 10.1254/fpj.153.192.
9
Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.在胸器官移植受者中使用来特莫韦进行巨细胞病毒预防或治疗的单中心经验。
Transpl Infect Dis. 2019 Dec;21(6):e13166. doi: 10.1111/tid.13166. Epub 2019 Sep 18.
10
Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy.0.024%拉坦前列素贝诺酯眼药水治疗开角型青光眼：设计、研发及在治疗中的地位
Clin Ophthalmol. 2018 Dec 20;12:2649-2657. doi: 10.2147/OPTH.S156038. eCollection 2018.
引用本文的文献
1
Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review.0.024%拉坦前列素倍他洛尔滴眼液在青光眼治疗中的真实世界影响：一项叙述性综述
Front Ophthalmol (Lausanne). 2025 Mar 28;5:1554777. doi: 10.3389/fopht.2025.1554777. eCollection 2025.
2
Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.拉坦前列素贝诺酯：首款释放一氧化氮的抗青光眼药物。
Med Gas Res. 2025 Jun 1;15(2):220-227. doi: 10.4103/mgr.MEDGASRES-D-24-00023. Epub 2024 Dec 7.
3
Dietary Nitrate Metabolism in Porcine Ocular Tissues Determined Using N-Labeled Sodium Nitrate Supplementation.使用 N 标记的硝酸钠补充剂测定猪眼组织中的膳食硝酸盐代谢。
Nutrients. 2024 Apr 13;16(8):1154. doi: 10.3390/nu16081154.
4
Recent advances on endogenous gasotransmitters in inflammatory dermatological disorders.炎症性皮肤疾病中内源性气体信号分子的最新进展。
J Adv Res. 2021 Sep 1;38:261-274. doi: 10.1016/j.jare.2021.08.012. eCollection 2022 May.
5
Potential roles of nitrate and nitrite in nitric oxide metabolism in the eye.硝酸盐和亚硝酸盐在眼部一氧化氮代谢中的潜在作用。
Sci Rep. 2020 Aug 5;10(1):13166. doi: 10.1038/s41598-020-69272-9.
6
Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy.0.024%拉坦前列素贝诺酯眼药水治疗开角型青光眼：设计、研发及在治疗中的地位
Clin Ophthalmol. 2018 Dec 20;12:2649-2657. doi: 10.2147/OPTH.S156038. eCollection 2018.
7
Transcriptional profiling of eosinophil subsets in interleukin-5 transgenic mice.白细胞介素-5 转基因小鼠嗜酸性粒细胞亚群的转录谱分析。
J Leukoc Biol. 2018 Jul;104(1):195-204. doi: 10.1002/JLB.6MA1117-451R. Epub 2018 May 14.
Zotero 插件